What is Lifesci Capital’s Estimate for AVDL Q1 Earnings?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Research analysts at Lifesci Capital issued their Q1 2025 earnings per share estimates for shares of Avadel Pharmaceuticals in a research note issued on Monday, March 3rd. Lifesci Capital analyst M. Belghiti forecasts that the company will post earnings of ($0.04) per share for the quarter. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals’ Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.12 EPS and FY2025 earnings at $0.15 EPS.

AVDL has been the topic of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price target on shares of Avadel Pharmaceuticals in a research note on Tuesday. Piper Sandler dropped their target price on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Deutsche Bank Aktiengesellschaft started coverage on Avadel Pharmaceuticals in a report on Tuesday, February 11th. They issued a “buy” rating and a $12.00 price target for the company. UBS Group dropped their price objective on Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, January 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Avadel Pharmaceuticals in a research note on Monday. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $19.88.

Avadel Pharmaceuticals Stock Up 3.0 %

AVDL opened at $7.87 on Wednesday. The firm’s 50 day moving average is $8.72 and its 200-day moving average is $11.48. Avadel Pharmaceuticals has a 52-week low of $7.39 and a 52-week high of $19.09. The firm has a market capitalization of $758.37 million, a P/E ratio of -9.96 and a beta of 1.28.

Insiders Place Their Bets

In other Avadel Pharmaceuticals news, Director Linda Palczuk acquired 3,000 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was acquired at an average price of $10.19 per share, with a total value of $30,570.00. Following the transaction, the director now directly owns 66,400 shares in the company, valued at approximately $676,616. This represents a 4.73 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Thomas S. Mchugh acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were acquired at an average price of $10.49 per share, for a total transaction of $52,450.00. Following the purchase, the chief financial officer now owns 85,500 shares of the company’s stock, valued at $896,895. This trade represents a 6.21 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 55,579 shares of company stock valued at $526,363 in the last quarter. Insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Avadel Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC bought a new stake in shares of Avadel Pharmaceuticals in the 3rd quarter worth approximately $31,000. Advisors Asset Management Inc. increased its position in Avadel Pharmaceuticals by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock worth $104,000 after buying an additional 2,846 shares during the period. Hsbc Holdings PLC bought a new stake in Avadel Pharmaceuticals in the fourth quarter valued at $113,000. Kazazian Asset Management LLC acquired a new position in shares of Avadel Pharmaceuticals during the fourth quarter valued at $126,000. Finally, Sanctuary Advisors LLC bought a new position in shares of Avadel Pharmaceuticals during the fourth quarter worth about $140,000. 69.19% of the stock is currently owned by institutional investors and hedge funds.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.